Adding Mass Selective Detection to Improve Analytical Sensitivity and Maximize Confidence in Results for Impurity Profiling by UHPLC

Importance of the Topic

Accurate impurity profiling of active pharmaceutical ingredients (APIs) is a cornerstone of drug quality assurance, helping to guarantee patient safety and regulatory compliance. Traditional UHPLC with UV detection is robust and user-friendly, but it can struggle with coeluting peaks and impurities that exhibit weak or no UV absorbance. Integrating mass-selective detection can overcome these challenges by providing orthogonal confirmation of analyte identity and enhancing sensitivity.

Objectives and Study Overview

This study evaluated the addition of a single-quadrupole mass selective detector (Agilent InfinityLab LC/MSD XT) in series with a diode-array UV detector to improve impurity profiling of Enalapril maleate. Key goals included demonstrating unambiguous peak identification, detection of low-UV-active species, resolution of coelutions, and compound confirmation through library searches.

Methodology

Enalapril maleate and related impurity standards were prepared in methanol. An MS-compatible mobile phase (0.1% formic acid in water and methanol) replaced non-volatile buffers. Chromatography employed a Poroshell EC-C18 column at 55 °C with a gradient from 20% to 90% organic over 12 minutes at 0.8 mL/min. A divert valve routed the main API peak at high concentration to waste before MS to protect the source. UV detection was monitored at 215 nm, while the MSD scanned 65–600 m/z at 40 Hz.

Instrumentation Used

• Agilent 1260 Infinity II Binary Pump
• Agilent 1260 Infinity II Sampler
• Agilent 1260 Infinity II Diode Array Detector
• Agilent InfinityLab LC/MSD XT with ESI-AJS interface
• Agilent OpenLAB CDS software for data acquisition, processing, library searching, and compliance

Main Results and Discussion

UV data identified seven impurity peaks with the API area at 98.7%, but low absorbance limited confidence at trace levels. MS detection revealed two additional impurity peaks not visible by UV and confirmed low-UV species by m/z. Extracted ion chromatograms allowed clear visualization of each impurity, including one at m/z 280 eluting at 2.5 minutes, identified with >96% library match as Impurity B. Coelution that masked peaks in the UV trace was resolved: distinct m/z signals (e.g., 383, 405) were attributed to separate impurities within a single UV peak. The divert valve maintained retention time reproducibility while preserving source cleanliness.

Benefits and Practical Applications

• Enhanced sensitivity for weak-absorbing or non-UV active impurities
• Unambiguous peak identification via mass spectra and library matching
• Resolution of coeluting compounds through extracted ion chromatograms
• Improved confidence in impurity quantitation and out-of-specification investigations
• Streamlined QC workflow with robust software compliance features

Future Trends and Applications

Advances in compact MS detectors and data processing will further integrate mass detection into routine QC, leading to automated library searches and real-time impurity alerts. High-resolution mass spectrometry and advanced fragment analysis will enable structural elucidation of unknown degradants, supporting accelerated drug development and regulatory submissions.

Conclusion

Coupling single-quadrupole mass detection to UHPLC-UV significantly elevates impurity profiling by revealing undetected species, resolving coelutions, and enabling confident compound confirmation. This approach empowers pharmaceutical laboratories to achieve higher analytical sensitivity and data integrity in routine QC operations.